- Home
- DBI vs OBIO Comparison
DBI vs OBIO Comparison
Compare DBI & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBI
- OBIO
- Stock Information
- Founded
- DBI 1991
- OBIO 2017
- Country
- DBI United States
- OBIO United States
- Employees
- DBI N/A
- OBIO N/A
- Industry
- DBI Clothing/Shoe/Accessory Stores
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- DBI Consumer Discretionary
- OBIO Health Care
- Exchange
- DBI Nasdaq
- OBIO Nasdaq
- Market Cap
- DBI 137.2M
- OBIO 151.3M
- IPO Year
- DBI 1991
- OBIO N/A
- Fundamental
- Price
- DBI $3.30
- OBIO $2.65
- Analyst Decision
- DBI Hold
- OBIO Strong Buy
- Analyst Count
- DBI 2
- OBIO 5
- Target Price
- DBI $4.75
- OBIO $14.20
- AVG Volume (30 Days)
- DBI 1.5M
- OBIO 959.6K
- Earning Date
- DBI 06-03-2025
- OBIO 05-16-2025
- Dividend Yield
- DBI 6.07%
- OBIO N/A
- EPS Growth
- DBI N/A
- OBIO N/A
- EPS
- DBI N/A
- OBIO N/A
- Revenue
- DBI $3,009,262,000.00
- OBIO $2,638,000.00
- Revenue This Year
- DBI $2.22
- OBIO $13.87
- Revenue Next Year
- DBI $2.18
- OBIO $32.19
- P/E Ratio
- DBI N/A
- OBIO N/A
- Revenue Growth
- DBI N/A
- OBIO N/A
- 52 Week Low
- DBI $2.44
- OBIO $2.43
- 52 Week High
- DBI $11.06
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- DBI 57.04
- OBIO 43.61
- Support Level
- DBI $2.78
- OBIO $2.37
- Resistance Level
- DBI $3.38
- OBIO $2.99
- Average True Range (ATR)
- DBI 0.17
- OBIO 0.33
- MACD
- DBI 0.11
- OBIO 0.05
- Stochastic Oscillator
- DBI 90.00
- OBIO 32.18
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.